Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/investing.ico', homepage_url='https://www.investing.com/', logo_url='https://s3.massive.com/public/assets/news/logos/investing.png', name='Investing.com')•2026-02-09
3 Stocks Trading Near $5 With Massive Earnings UpsideIRWD — Ironwood Pharmaceuticals Inc
NASDAQ · Biotechnology · Biotechnology
$4.07+13.37%Market cap577.23M
- Latest Close
- $4.07
- 30-Day Move
- +13.4%
- Market Cap
- $577M
- Shares Outstanding
- 163,060,000
- P/E Ratio
- 24.03
- P/B Ratio
- 2.91
NASDAQ:IRWDBiotechnology / BiotechnologyDelayed public snapshot
Ironwood Pharmaceuticals Inc
A read-only Alphactor snapshot forIronwood Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$4.07
30-Day Move
+13.4%
Market Cap
$577M
Shares Outstanding
163,060,000
P/E Ratio
24.03
P/B Ratio
2.91
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$4.07
+13.4%last 90 delayed daily bars
Market cap$577M
90D High
$5.78
90D Low
$2.95
Avg Volume
3,868,281
What stands out
Gross margin is running at 100.0%, which gives a quick read on operating quality before you open the full model.
Net margin is 8.1%, useful for comparing IRWD against peers in Biotechnology.
IRWD is up 13.4% over the last 30 trading days shown on this page.
Latest operating income is $119M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$4.80
Rule of 40
27.2%
Dark Pool Short %
50.9%
Fundamentals snapshot
Latest Close
$4.07
30-Day Move
+13.4%
Market Cap
$577M
Shares Outstanding
163,060,000
P/E Ratio
24.03
P/B Ratio
2.91
ROE
26.8%
ROA
6.0%
Gross Margin
100.0%
Operating Margin
33.3%
Net Margin
8.1%
Debt / Equity
0.61
Current Ratio
1.13
Latest Revenue
$296M
Financial statement snapshot
Revenue
$296M
Gross Profit
--
Operating Income
$119M
Net Income
$24M
Gross Margin
10000.0%
Net Margin
811.0%
Current Ratio
1.13
Debt / Equity
0.61
Valuation snapshot
Fair Value
$4.80
Upside / Downside
+18.0%
Signal
Fairly Valued
Implied Growth
-6.1%
DCF
$3.80
EPV
$3.87
EV/Rev
$6.74
Growth Assumption
-10.0%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$127M
Valuation spread
Current Price
$4.07
Composite Fair Value
$4.80
DCF
$3.80
EPV
$3.87
EV/Rev
$6.74
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Quality snapshot
Altman Z
-3.55
Distress
Piotroski
6
Moderate (4-6)
Cash Conversion
5.29x
Rule of 40
27.2%
Acceptable
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $411M | $250M | $175M | $274M |
| 2023-12-31 | $443M | $168M | $-1.0B | $183M |
| 2024-12-31 | $351M | $96M | $880,000 | $103M |
| 2025-12-31 | $296M | $119M | $24M | $127M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-01-05
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/investing.ico', homepage_url='https://www.investing.com/', logo_url='https://s3.massive.com/public/assets/news/logos/investing.png', name='Investing.com')•2026-01-02
Ironwood Finds a New Floor as LINZESS Net Pricing Turns Into a Growth LeverPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2025-04-14
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal DrugPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2024-12-06
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$22M
Buys
0
Sells
22
Buy Value
$0
Sell Value
$22M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-17 | DENNER ALEXANDER J | Sell | 5,800 | $3.31 |
| 2026-03-17 | DENNER ALEXANDER J | Sell | 6,725,000 | $3.05 |
| 2026-03-13 | DENNER ALEXANDER J | A | 4,451 | $0.00 |
| 2026-03-10 | Gaskins Tammi L | A | 136,612 | $0.00 |
| 2026-03-10 | Shetzline Michael | A | 136,612 | $0.00 |
| 2026-03-10 | Silver Ronald | A | 163,934 | $0.00 |
| 2026-03-10 | John Minardo | A | 136,612 | $0.00 |
| 2026-03-10 | Martini Gregory S. | A | 136,612 | $0.00 |
Institutional holders snapshot
BlackRock
Filed 2024-05-10
$210M
--
Vanguard Group
Filed 2026-01-29
$54M
-0.7%
Renaissance Technologies
Filed 2026-02-12
$28M
-1.8%
Charles Schwab
Filed 2026-02-13
$17M
+1.2%
Marshall Wace
Filed 2026-02-13
$15M
--
Geode Capital Management
Filed 2026-02-09
$12M
+0.2%
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.